Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic rhTPO timing in relapsed or refractory lymphoma receiving intensive chemotherapy
ChiCTR1800018737Phase 4Not yet recruiting
- Sponsor
- Tongji Medical College
- Start
- Jan 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human thrombopoietin in lymphoma (2 arms), sponsored by Tongji Medical College. Primary endpoint: Platelet minimum. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
lymphoma
Beyond the preview
Go deeper on ChiCTR1800018737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018737.